Genotype, viral load and age as independent predictors of treatment outcome of interferon-α2a treatment in patients with chronic hepatitis C

Scandinavian Journal of Infectious Diseases

Volumn 29, Issue 1, 1997, Pages 17-22

  Bell, Helge ^a   Hellum, Kjell ^b   Harthug, Stig ^c   Mland, Arild ^d   Ritland, Stale ^e   Myrvang, Bjørn ^f   Von Der Lippe, Bent ^g   Raknerud, Nils ^h   Skaug, Kjell ⁱ   Gutigard, Bjørg Guri ^j   Skerven, Rolv ^a   Prescott, Linda E ^b   Simmonds, Peter ^c  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b Departments of Medicine   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f Central Hospital of Buskerud   (Norway)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h UNIVERSITY OF BERGEN   (Norway)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

^j Medical Departments of Basrum Hospital

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON;

ADULT; AGE; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERMETHOD COMPARISON; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; VIRUS PARTICLE;

EID: 0346720473     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365549709008658     Document Type: Article

References (37)

1. Hoofnagle JH, Müllen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha-interferon: A preliminary report. N Engl J Med 315: 1575-1578, 1986.
2. Davis GL, Baiart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas Aand the Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized, controlled trial. N Engl J Med 321: 1501-1506, 1989.
3. Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomized clinical trials. J Hepatology 13: 192-199, 1991.
4. Reichard O, Foberg U, Fryden A, Mattson L, Norkrans G, Sonnerborg A, Wejstâl R, Yun ZB, Weiland O. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha-2b for 60 weeks. Hepatology 19: 280-285, 1994.
5. Lindsay KL, Davis GL, Schiff R, Bodenheimer H, Baiart L, Dienstag J, Perrillo R, Tamburro C, Silva M, Goff C, Everson G, Sanghvi B, Albrecht J. Long-term response to higher doses of interferon (IFN) alpha-2b treatment of patients with chronic hepatitis C: A randomized multicenter trial. Hepatology 18: 106A, 1993.
6. Bjoro K, Krarup H, Bell H, Christoffersen P, Evensen S, Froland SS, Laursen A, von der Lippe B, Mæland A, Ranek L, Ring-Larsen H, Schou G, Schrumpf E, Tygstrup N. Two dose regimens of recombinant interferon-alpha-2b in chronic hepatitis C infection. Biochemistry, hepatitis C virus RNA, and liver histology as response indices. Scand J Gastroenterol 30: 1119-1124, 1995.
7. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1: 431-435, 1981.
8. Young KKY, Resnick RM, Myers TW. Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol 31: 882-886, 1993.
9. Bhattacherjee V, Prescott LE, Pike I, Rodgers B, Bell H, El-Zaiadi AR, Kew MC, Conradie J, Lin CK, Marsden H, Saed AA, Parker D, Yap, P-L, Simmonds P. Use of NS-4 peptides to identify type-specific antibody to hepatitis C virus genotypes 1,2, 3,4, 5 and 6. J Gen Virol 76: 1737-1748, 1995.
10. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Sem Liv Dis 5: 82-91, 1995.
11. Ryff J-C. Usefulness of interferon treatment of hepatitis C. J Hepatology 22 Suppl 1: 101-109, 1995.
12. Brouwer JT, Nevens F, Kleter GEM, Elewaut A, Adler M, Brenard R Chamuleau RAFM, Michielsen P, Pirotte J, Hautekeete ML, Arendt B, Fevery J, Schalm SW. Efficacy of interferon dose and factors predictive of sustained response in chronic hepatitis C: final results of a Benelux multicenter study in 350 patients. J Hepatology 23 Suppl 1: 85, 1995 (Abstract WP4/25).
13. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo B, Cerutti E, Di Napoli A, Solinas A, Deplano A, Tocco A, Cossu P, Chien D, Kuo G, Polito A, Weiner AJ, Houghton M, Verme G, Bonino F, Rizetto M. Long-term follow-up patients with chronic hepatitis C treated with different doses of interferon-a2b. Hepatology 18: 1300-1305, 1993.
14. Diodati G, Bonetti P, Noventa F, Casarin C, Rugge M, Scaccabarozzi S, Tagger A, Pollice L, Tremolada F, Davite C, Realdi G, Ruol A. Treatment of chronic hepatitis C with recombinant human interferon-α2a: Results of a randomized controlled clinical trial. Hepatology 19: 1-5, 1994.
15. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vinaud M, Chaput JC and the Multicenter Study Group. A comparison of three interferon alpha-2b regimens for the long term treatment of chronic non-A, non-B hepatitis. N Engl J Med 332: 1457-1462, 1995.
16. Tisminetzky SG, Gerotto M, Pontisso P, Chemello L, Ruv elotto MG, Barelle F, Alberti A. Genotypes of hepatitis C virus in Italian patients with chronic hepatitis C. Int Hepatol Commun 2: 105-112, 1994.
17. Takada N, Takase S, Enomoto N, Takada A, Date T. Clinical backgrounds of the patients having different types of hepatitis C virus genomes. J Hepatology 14: 35-40, 1992.
18. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itol Y, Takayanagi M, Higashi Y, Shibata M and Morishima T. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-a therapy: relationship to genotypes of hepatitis C virus. Hepatology 16: 293-299, 1992.
19. Hino HK, Sainokami S, Shimoda K, lino S, Wang, Y, Okamoto H, Miyakawa Y, Mayumi M. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 42: 299-305, 1994.
20. Tsubota A, Chayama K, Arase Y, Koida I, Saitoh S, Ikeda K, Iwasaki S, Matsumoto T, Kobayashi M, Kumuda H. Factors useful in predicting the response to .interferon therapy in chronic hepatitis C. J Gastroenterol Hepatol 8: 535-539, 1993.
21. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Hiromitsu K. Factors predictive of response to interferon-a therapy in hepatitis C virus infection. Hepatology 19: 1088-1094, 1994.
22. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 339: 1543, 1992.
23. Kobayashi Y, Watanabe S, Konishi M, Yokoi M, Kakehashi R, Kaito M, Kondo M, Hayashi Y, Jomori T and Suzuki S. Quantification and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-β. Hepatology 18: 1319-1325, 1993.
24. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap P-L, Sherlock S, Mclntyre N, Simmonds P. Hepatitic C virus genotypes: An investigtion of type specific differences in geographic origin and disease. Hepatology 19: 13-18, 1994.
25. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M, Noventa F, Pontisso P, Benvegnu L, Casarin C, Albert! A, and the TriVeneto Viral Hepatitis group. Randomized trial comparing three different regimens of alpha-2a interferon in chronic hepatitis type C. Hepatology 22: 700-706, 1995.
26. Yamada G, Takahashi M, Miyamoto R, Tsuji T, Yoshizava H, Okamoto H. Prediction of interferon effect in chronic hepatitis C by both quantification and genotyping of HCV RNA. Dig Dis Sci 39: 441-444, 1994.
27. Chayama K, Arase Y, Koida I, Tsubota A, Saitoh S, Ikeda K, Matsumoto T, Kanda M, Iwasaki S, Kobayashi M. Antiviral effect of lymphoblastoid interferon-alpha on hepatitis C virus in patients with chronic hepatitis C. J Gastroenterol Hepatol 9: 128-133, 1994.
28. Brechot C. Hepatitis C virus genetic variability: Clinical implications. Am J Gastroenterol 89: S41-S47, 1994.
29. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, Masuzawa M, Yoshihara H, Kishida Y, Shimizu Y, Inoue A, Fusamoto H, Kamada T. Ability , of prolonged Interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C. A multicenter randomized controlled trial. Hepatology 21: 291-297, 1995.
30. Simmonds P. Variability of hepatitis C virus. Hepatology 21: 570-583, 1995.
31. Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341: 1501-1504, 1993.
32. Nousbaum J-B Stanislas P, Nalpas B, Landais P, Berthelot P, Brechot C and the Collaborative Study Group. Hepatitis C virus type Ib (II). Infection in France and Italy. Ann Int Med 122: 161-168, 1995.
33. Smith DB, Davidson F, Yap, P-E, Brown H, Kolberg J, Detmer J, Urdea M, Simmonds P and thé International HCV Collaborative Study Group. Levels of hepatitis C virus in blood donors infected with different viral genotypes. J Infect Dis 173: 727-730, 1996.
34. Pissinino F, Felaco FM, Aprea L, Messina V, Pasquale G, Sagnelli E. Non responders to interferon therapy among chronic hepatitis patients infected with hepatitis C virus. Arch Virol SuppI 8: 257-263, 1993.
35. Uchida T, Taira M, Shigata T, Moriyama M, Tanaka N, Okubo H, Arakawa Y. Histological differences between complete responders and non-responders to interferon therapy of the livers of patients with chronic hepatitis C. Acta Pathol Jpn 43: 230-236, 1993.
36. Ferez R, Pravïa R, Linares A, Rodriguez M, Lombrana JLS, Suarez A, Riestra S, Navascues CA, Rodrigo L. Response related factors in recombinant interferon alpha-2b treatment of chronic hepatitis C. Gut Suppl 34: S139-S140, 1994.
37. Camps J, Chrisostomo S, Garcia-Granero M, Riezu-Boi JI, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon-alpha: a statistical analysis of pretreatment variables. Gut 34: 1714-1717, 1993.